<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611010</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-1103-002</org_study_id>
    <nct_id>NCT03611010</nct_id>
  </id_info>
  <brief_title>Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients</brief_title>
  <official_title>Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously Controlled With Oral Atorvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C
      levels in hypercholesterolemic patients previously controlled on oral atorvastatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">February 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, Low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>15 Days</time_frame>
    <description>At least 11 of 13 subjects in a cohort that maintain LDL-C not more than 125% of their baseline level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, High -density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>15 Days</time_frame>
    <description>At least 11 of 13 subjects in a cohort that maintain HDL-C not more than 125% of their baseline level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change, LDL-C</measure>
    <time_frame>15 days</time_frame>
    <description>The mean change in LDL-C from baseline to end of treatment across the cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax IV</measure>
    <time_frame>24 hours</time_frame>
    <description>The maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve to infinity of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve from administration to Hour 24 of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-1/2 IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Elimination serum half-life of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VDss IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Volume of distribution of atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Elimination rate constant for atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl IV</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma clearance calculated for atorvastatin and the 2- and 4-hydroxy active metabolites following an intravenous injection to a patient at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum serum concentration of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve to infinity of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-1/2 SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Elimination serum half-life of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VDss SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Volume of distribution of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Elimination rate constant of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl/F SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Apparent clearance of atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl SC</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma clearance calculated for atorvastatin and the 2- and 4-hydroxy active metabolites following a single subcutaneous injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>10 mg oral atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg oral atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg oral atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg oral atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin injection</intervention_name>
    <description>statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection</description>
    <arm_group_label>10 mg oral atorvastatin</arm_group_label>
    <arm_group_label>20 mg oral atorvastatin</arm_group_label>
    <arm_group_label>40 mg oral atorvastatin</arm_group_label>
    <arm_group_label>80 mg oral atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On stable dose of daily oral atorvastatin for &gt;= 5 weeks (oral atorvastatin may be
             provided during a lead-in period for subjects not previously taking atorvastatin)

          -  Stable LDL-C confirmed in the previous 7 to 10 days prior to enrollment into the
             treatment phase.

        Exclusion Criteria:

          -  History of myopathy or rhabdomyolysis

          -  Liver disease including current biliary disorders

          -  Positive for HIV, Hepatitis B or Hepatitis C Virus

          -  Abuse of alcohol or non-prescribed drugs

          -  Unstable angina or arrhythmias or a cardiac event in the previous three months

          -  hypothyroidism, diabetes, or hypertension that is not under control

          -  pregnant or plans to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Tracey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frontage Lab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage Clinical Services</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

